Our group has carried out bi-directional technology transfer between clinical and basic AIDS research in HIV in pioneering the first ACTG trial (ACTG 244) which uses drug/virus response driven therapy. This has been accomplished, in part, through the development of a monitoring system based on quantitative RNA PCR that allows rapid assessment of the pivotal pol gene mutations involved in ZDV resistance. This sort of response driven therapy has emerged as a new option in the development of HIV therapeutics, given the ability of the virus to produce variants, including drug escape mutants. We propose to incorporate this approach in an effort to evaluate HIV antigen specific cellular immunotherapies in man. Clinical virologists and immunologists together with cell biologists at Stanford University have combined with a cell therapy company, recombinant vaccine and cytokine manufacturers and a gene therapy developer at Duke University to prepare and administer, in vivo, antigen presenting cells as well as HIV specific cytolytic T cells. This collaboration should bring to HIV infected patients the products of biotechnology firms as well as those of our academic institution. Our extensive experience, beginning almost two decades ago, in defining and optimizing ways of utilizing human interferon in man should facilitate our proposed academic-industrial collaboration, with clinical results available within the tenure of the proposed grant. Pilot clinical trials will be monitored with new methods and conducted with new modalities supported by the grant. The latter will also support the background pathogenetic and disease monitoring required for achieving the goals of the project. Subsequent large scale clinical trials will require industrial or ACTG support, which is already in place for the first phase of the proposed studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI036608-04
Application #
2429440
Study Section
Special Emphasis Panel (SRC (72))
Project Start
1994-09-01
Project End
1999-12-31
Budget Start
1997-06-01
Budget End
1999-12-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Shapero, M H; Kundu, S K; Engleman, E et al. (2000) In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant 9:307-17
Peshwa, M V; Benike, C; Dupuis, M et al. (1998) Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell Transplant 7:1-9
Kundu, S K; Engleman, E; Benike, C et al. (1998) A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 14:551-60
Engleman, E G (1997) Dendritic cells: potential role in cancer therapy. Cytotechnology 25:1-8
Takamizawa, M; Rivas, A; Fagnoni, F et al. (1997) Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. J Immunol 158:2134-42
Dupuis, M; Peshwa, M V; Benike, C et al. (1997) Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. AIDS Res Hum Retroviruses 13:33-9
Mehta-Damani, A; Markowicz, S; Engleman, E G (1995) Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol 25:1206-11
Fagnoni, F F; Takamizawa, M; Godfrey, W R et al. (1995) Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Immunology 85:467-74